Role of Gender and Physical Activity Level on Cardiovascular Risk Factors and Biomarkers of Oxidative Stress in the Elderly.


Journal

Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826

Informations de publication

Date de publication:
2020
Historique:
received: 19 02 2020
revised: 12 05 2020
accepted: 25 05 2020
entrez: 14 7 2020
pubmed: 14 7 2020
medline: 6 5 2021
Statut: epublish

Résumé

Cardiovascular diseases remain as the leading cause of morbidity and mortality in industrialized countries. Ageing and gender strongly modulate the risk to develop cardiovascular diseases but very few studies have investigated the impact of gender on cardiovascular diseases in the elderly, which represents a growing population. The purpose of this study was to test the impact of gender and physical activity level on several biochemical and clinical markers of cardiovascular risk in elderly individuals. Elderly individuals (318 women (75.8 ± 1.2 years-old) and 227 men (75.8 ± 1.1 years-old)) were recruited. Physical activity was measured by a questionnaire. Metabolic syndrome was defined using the National Cholesterol Education Program Expert Panel's definition. Polysomnography and digital tonometry were used to detect obstructive sleep apnea and assess vascular reactivity, respectively. Blood was sampled to measure several oxidative stress markers and adhesion molecules. The frequency of cardiovascular diseases was significantly higher in men (16.4%) than in women (6.1%) ( These findings suggest that biochemical cardiovascular risk factors are lower in women than men which could explain the lower cardiovascular disease proportion observed in women in the elderly.

Sections du résumé

BACKGROUND BACKGROUND
Cardiovascular diseases remain as the leading cause of morbidity and mortality in industrialized countries. Ageing and gender strongly modulate the risk to develop cardiovascular diseases but very few studies have investigated the impact of gender on cardiovascular diseases in the elderly, which represents a growing population. The purpose of this study was to test the impact of gender and physical activity level on several biochemical and clinical markers of cardiovascular risk in elderly individuals.
METHODS METHODS
Elderly individuals (318 women (75.8 ± 1.2 years-old) and 227 men (75.8 ± 1.1 years-old)) were recruited. Physical activity was measured by a questionnaire. Metabolic syndrome was defined using the National Cholesterol Education Program Expert Panel's definition. Polysomnography and digital tonometry were used to detect obstructive sleep apnea and assess vascular reactivity, respectively. Blood was sampled to measure several oxidative stress markers and adhesion molecules.
RESULTS RESULTS
The frequency of cardiovascular diseases was significantly higher in men (16.4%) than in women (6.1%) (
CONCLUSION CONCLUSIONS
These findings suggest that biochemical cardiovascular risk factors are lower in women than men which could explain the lower cardiovascular disease proportion observed in women in the elderly.

Identifiants

pubmed: 32655757
doi: 10.1155/2020/1315471
pmc: PMC7321518
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1315471

Informations de copyright

Copyright © 2020 Antoine Raberin et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Panminerva Med. 2013 Jun;55(2):191-5
pubmed: 23676959
Br J Sports Med. 2012 Jul;46(9):664-8
pubmed: 22219216
Diabetologia. 2010 Sep;53(9):1877-85
pubmed: 20495973
Circulation. 2016 Mar 29;133(13):1302-31
pubmed: 26927362
Cardiovasc Res. 2014 Aug 1;103(3):341-9
pubmed: 24935434
BMJ. 2012 Oct 09;345:e6409
pubmed: 23048011
Int J Biol Sci. 2013 Nov 09;9(10):1057-69
pubmed: 24250251
Eur Heart J. 2001 Apr;22(7):573-9
pubmed: 11259144
Neuroepidemiology. 2007;29(1-2):18-28
pubmed: 17898520
PLoS One. 2015 Sep 14;10(9):e0137957
pubmed: 26368280
CMAJ. 1999;161(8 Suppl):S3-9
pubmed: 10551206
Eur J Heart Fail. 2004 Aug;6(5):577-84
pubmed: 15302005
J Am Heart Assoc. 2016 Apr 18;5(4):e002544
pubmed: 27091178
Age Ageing. 2000 Sep;29(5):433-9
pubmed: 11108416
Prev Med. 2004 Nov;39(5):1056-61
pubmed: 15475041
Climacteric. 2007 Feb;10 Suppl 1:19-24
pubmed: 17364594
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Arch Intern Med. 2004 May 24;164(10):1066-76
pubmed: 15159263
J Am Coll Cardiol. 2006 Apr 18;47(8):1588-94
pubmed: 16630995
Clin Geriatr Med. 2009 Nov;25(4):563-77, vii
pubmed: 19944261
Indian J Med Res. 2013 Jan;137(1):117-24
pubmed: 23481060
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
PLoS One. 2013 Jul 30;8(7):e65174
pubmed: 23935815
Diabetes Metab. 2006 Nov;32(5 Pt 1):467-74
pubmed: 17110902
BMC Public Health. 2013 May 06;13:449
pubmed: 23648225
Am J Physiol Heart Circ Physiol. 2010 Apr;298(4):H1146-54
pubmed: 20139324
Atherosclerosis. 2015 Jul;241(1):205-7
pubmed: 26003338
Am J Respir Crit Care Med. 2008 Feb 15;177(4):369-75
pubmed: 17975198
Proc Am Thorac Soc. 2008 Feb 15;5(2):136-43
pubmed: 18250205
Atherosclerosis. 2009 Oct;206(2):611-6
pubmed: 19375079
Am J Cardiol. 2006 Jan 1;97(1):141-7
pubmed: 16377300
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Trends Cardiovasc Med. 2009 Jan;19(1):6-11
pubmed: 19467447
Curr Opin Nephrol Hypertens. 2011 Mar;20(2):133-8
pubmed: 21178615
Biogerontology. 2016 Jun;17(3):567-80
pubmed: 26936444
Heart. 2016 Jun 1;102(11):825-31
pubmed: 26917537
Vascul Pharmacol. 2018 Jan;100:1-19
pubmed: 28579545
Aging Clin Exp Res. 2015 Aug;27(4):547-53
pubmed: 25835220
JAMA. 2004 Sep 22;292(12):1433-9
pubmed: 15383513
Hypertension. 2005 Jan;45(1):142-61
pubmed: 15611362

Auteurs

Antoine Raberin (A)

Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell », Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.

Philippe Connes (P)

Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell », Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.
Institut Universitaire de France, Paris, France.

Jean-Claude Barthélémy (JC)

Service de Physiologie Clinique et de l'Exercice, Faculté de Médecine Jacques Lisfranc, Univ Lyon, Université Jean Monnet, Saint-Etienne, France.
Laboratoire Système Nerveux Autonome-Epidémiologie, Physiologie, Ingénierie, Santé, EA SNA-EPIS 4607, Université de Lyon, Université Jean Monnet Saint-Etienne, France.

Pia Robert (P)

Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell », Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.

Sébastien Celle (S)

Service de Physiologie Clinique et de l'Exercice, Faculté de Médecine Jacques Lisfranc, Univ Lyon, Université Jean Monnet, Saint-Etienne, France.
Laboratoire Système Nerveux Autonome-Epidémiologie, Physiologie, Ingénierie, Santé, EA SNA-EPIS 4607, Université de Lyon, Université Jean Monnet Saint-Etienne, France.

David Hupin (D)

Service de Physiologie Clinique et de l'Exercice, Faculté de Médecine Jacques Lisfranc, Univ Lyon, Université Jean Monnet, Saint-Etienne, France.
Laboratoire Système Nerveux Autonome-Epidémiologie, Physiologie, Ingénierie, Santé, EA SNA-EPIS 4607, Université de Lyon, Université Jean Monnet Saint-Etienne, France.

Camille Faes (C)

Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell », Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.

Chantal Rytz (C)

Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Frédéric Roche (F)

Service de Physiologie Clinique et de l'Exercice, Faculté de Médecine Jacques Lisfranc, Univ Lyon, Université Jean Monnet, Saint-Etienne, France.
Laboratoire Système Nerveux Autonome-Epidémiologie, Physiologie, Ingénierie, Santé, EA SNA-EPIS 4607, Université de Lyon, Université Jean Monnet Saint-Etienne, France.

Vincent Pialoux (V)

Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell », Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.
Institut Universitaire de France, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH